CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

Inclusion Criteria:

- One of the following diagnoses:

- MDS with International Prostate Symptom Score (IPSS) score of INT-1 or higher and
one of the following:

- Symptomatic anemia with either hemoglobin < 10.0 g/dL or requiring red blood
cell (RBC) transfusion

- Thrombocytopenia with a history of two or more platelet counts < 50,000/µL
or a significant hemorrhage requiring platelet transfusions

- Neutropenia with two or more absolute neutrophil count (ANC) < 1,000/µL

- Non-M3 AML

- Prior treatment with ≥ 4 cycles of a hypomethylating agent (decitabine or azacitidine)
without response OR documented disease progression on or after hypomethylating agent
therapy

- Age ≥ 18 years old

- Adequate renal and hepatic function defined as all of the following:

- total bilirubin ≤ 1.5 x upper limit of normal (ULN), except in cases of Gilbert's
disease

- aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN

- serum creatinine < 2.0 x ULN

- Peripheral blood blast count < 10,000/ µL.

- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

- Females must be surgically or biologically sterile or postmenopausal or, if of
childbearing potential, must agree to use an adequate method of contraception during
the study until 30 days after the last treatment. Males must be surgically or
biologically sterile or agree to use an adequate method of contraception during the
study until 30 days after the last treatment.

- Ability to understand and willingness to sign an IRB approved written informed consent
document (or that of legally authorized representative, if applicable).

Exclusion Criteria:

- Prior allogeneic stem cell transplant

- Central nervous system (CNS) leukemia

- Diagnosed with AML and eligible for standard induction chemotherapy or stem cell
transplantation.

- At an increased risk of hemorrhage.

- Known allergies, hypersensitivity, or intolerance to any form of heparin or
azacitidine

- Presence of significant active bleeding or condition requiring maintenance of a
platelet count > 50,000/µL

- Presence of any condition requiring any form of anticoagulant therapy (heparin flushes
for IV catheter are permitted)

- Receiving concomitant chemotherapy, radiation therapy, or immunotherapy during the
duration of treatment on protocol, or within 21 days prior to enrollment

- Known seropositivity for or active viral infection with human immunodeficiency virus
(HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). Patients who are
seropositive because of hepatitis B virus vaccine are eligible.

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac
arrhythmia

- Pregnant and/or breastfeeding. Women of childbearing potential must have a negative
pregnancy test within 28 days of study entry.